+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07864207

Phase 12 Open-label Multicenter Study of IDP-121 Combined with Chemotherapy in Patients with Platinum-Resistant Small Cell Lung Cancer

Led by IDP Discovery Pharma S.L. · Updated on 2026-10-07

60

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, how the body processes, and the effects of increasing doses of the drug IDP-121 combined with chemotherapy in patients with advanced small cell lung cancer SCLC that cannot be removed by surgery and has returned or worsened after initial platinum-based chemotherapy. This study also considers the role of MYC gene amplification in the development of resistance to platinum chemotherapy. The trial is a Phase 12, open-label study conducted at multiple centers. Participants receive IDP-121 combined with chemotherapy in one of two groups based on their progression-free interval after first-line treatment. One group receives IDP-121 with topotecan if their progression-free interval is less than 3 months, and the other group receives IDP-121 with platinum-based chemotherapy if their progression-free interval is 3 months or longer. The study uses a dose-escalation approach to assess different doses of IDP-121 alongside chemotherapy. During the study, participants will be closely monitored for safety and treatment effects including the maximum tolerated dose and recommended phase 2 dose over one year. Assessments include regular clinical evaluations and laboratory tests to check blood counts, liver and kidney function, and heart function via echocardiogram. Participants must comply with the study protocol and provide informed consent. The trial will continue until July 2028, with ongoing safety and effectiveness monitoring throughout.

CONDITIONS

Brief Title

Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

Research Team

D

David Molina, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here